Tempus AI (NASDAQ: TEM), a healthcare technology company, posted impressive Q1 results with revenue reaching $255.7 million, up 75.4% year-over-year. Adjusted EBITDA improved significantly to $-16.2 ...
CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide ...
Hosted on MSN
Tempus AI Expands “Tempus Next” Platform to Improve Breast Cancer Care with AI-Driven Insights.
Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the expansion of its care pathway intelligence platform, called Tempus Next, to ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
More than 7 million Americans are living with Alzheimer’s disease today, yet only a small fraction are evaluated for eligibility for approved treatments. The collaboration aims to narrow that gap by ...
The healthcare technology space is gaining enormous investors' attention these days, thanks to the rapid advancements in artificial intelligence (AI) in this niche. Companies like Tempus AI TEM are ...
Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient ...
Tempus AI TEM has recently expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer to address critical care gaps in breast cancer care. Initially designed for lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results